Evidence map›Paper›PMID 32508840›Full record

ArticleFrontiers in immunology2020

Enhanced Pro-apoptotic Effects of Fe(II)-Modified IVIG on Human Neutrophils.

Stefanie Graeter, Christoph Schneider, Daniëlle Verschoor, Sandro von Däniken, Frank Seibold, Nikhil Yawalkar, Peter Villiger, Jordan D Dimitrov, David F Smith, Richard D Cummings and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 6 countries.

Stefanie GraeterInstitute of Pharmacology, University of Bern, Bern, Switzerland.
Christoph SchneiderInstitute of Pharmacology, University of Bern, Bern, Switzerland.
Daniëlle VerschoorInstitute of Pharmacology, University of Bern, Bern, Switzerland.
Sandro von DänikenInstitute of Pharmacology, University of Bern, Bern, Switzerland.
Frank SeiboldCrohn-Colitis Zentrum, Hochhaus Lindenhofspital, Bern, Switzerland.
Nikhil YawalkarDepartement für Dermatologie, Urologie, Rheumatologie, Nephrologie, Physiologie, Inselspital Bern, University Hospital, Bern, Switzerland.
Peter VilligerUniversitätsklinik für Rheumatologie, Immunologie und Allergologie, Inselspital Bern, University Hospital, Bern, Switzerland.
Jordan D DimitrovCentre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université Paris Descartes, Université Paris Diderot, Paris, France.
David F SmithDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA, United States.
Richard D CummingsDepartment of Surgery and Harvard Medical School Center for Glycoscience, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, United States.
Hans-Uwe SimonInstitute of Pharmacology, University of Bern, Bern, Switzerland.
Tchavdar VassilevDepartment of Immunology, Stefan Angelov Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria.
Stephan von GuntenInstitute of Pharmacology, University of Bern, Bern, Switzerland.
University of Bern · CHEmory University · USUniversity Hospital of Bern · CHCentre de Recherche des Cordeliers · FRLindenhofspital · CHSechenov University · RUStephan Angeloff Institute of Microbiology · BG

Funding

Overall Priority Score P41GM103694 · NIGMS · EMORY UNIVERSITY · PI CUMMINGS, RICHARD D · 2013 to 2018
$6.9M
Protein-Glycan Interaction Resource at the National Center for Functional Glycomics (NCFG)R24GM137763 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI RICHARD D CUMMINGS · 2020 to 2026
$5.8M
NIGMS NIH HHS P41 GM103694NIGMS NIH HHS R24 GM137763
6 · The paper itself

Abstract

Mild modification of intravenous immunoglobulin (IVIG) has been reported to result in enhanced polyspecificity and leveraged therapeutic effects in animal models of inflammation. Here, we observed that IVIG modification by ferrous ions, heme or low pH exposure, shifted the repertoires of specificities in different directions. Ferrous ions exposed Fe(II)-IVIG, but not heme or low pH exposed IVIG, showed increased pro-apoptotic effects on neutrophil granulocytes that relied on a FAS-dependent mechanism. These effects were also observed in human neutrophils primed by inflammatory mediators or rheumatoid arthritis joint fluid

Indexed as

ApoptosisArthritis, RheumatoidCrohn DiseaseFerrous CompoundsHumansHydrogen-Ion ConcentrationImmunoglobulins, IntravenousNeutrophilsFerrous CompoundsImmunoglobulins, Intravenouscell deathFASinflammationmodified IVIGneutrophil

Identifiers

PMID32508840
PMCPMC7248553
OpenAlexW3026744080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.